A Phase IIIb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150microg o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Trial Profile

A Phase IIIb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150microg o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INFINITY
  • Sponsors Novartis
  • Most Recent Events

    • 21 May 2014 Planned End Date changed from 1 Feb 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 22 Mar 2013 Planned number of patients changed from 76 to 132 as reported by ClinicalTrials.gov.
    • 04 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top